Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

reMYND

Home Clinical Trial Sponsors and OrganizationsreMYND

reMYND

Gaston Geenslaan 1, Leuven, Vlaams Brabant, Belgium

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

6

1 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

4

66.7%

Phase 2

2

33.3%

Trial Status Distribution

Active, not recruiting

1

16.7%

Completed

1

16.7%

Recruiting

2

33.3%

Terminated

2

33.3%

Clinical Trials

Trials sponsored by this organization (6)

A Study to Investigate Safety, Tolerability and Pharmacokinetics of REM0045392 Compared With Placebo in Healthy Participants.

Mar 202519 participants

A Phase 2a, randomized, placebo-controlled, double-blind study to investigate REM0046127 in mild to moderate Alzheimer's disease

Active, not recruiting

Jun 202260 participants

A Phase 2a Study to Investigate REM0046127 in Mild to Moderate Alzheimer's Disease

Jun 202214 participants

A Phase 1 (First in Human) Randomized, Double-blind, Placebo-controlled SAD, MAD Study With Oral REM0046127

Nov 202077 participants

A randomized, placebo-controlled, double-blind, parallel-group Phase 2a exploratory study with placebo run-in to investigate PK/PD effects, safety, tolerability and pharmacokinetics of REM0046127 oral suspension compared with placebo in subjects with mild to moderate Alzheimer's disease

10 participants

A study to investigate safety, tolerability, pharmacokinetics and efficacy of REM0045392 compared with placebo in healthy participants

52 participants

Approvals

No approval data available

News

Pharmaceutical Industry Sees Wave of Board Appointments as Companies Strengthen Leadership

- Pharmaceutical and biotech companies across Europe and North America have made significant board appointments, bringing industry veterans and scientific experts to strengthen their leadership teams. - Notable appointments include former CDC Director Dr. Julie Louise Gerberding joining ARTIDIS and former Roche neuroscience head Dr. Paulo Fontoura taking on dual advisory roles. - Companies ranging from clinical-stage biotechs to established pharmaceutical firms are adding expertise in areas including oncology, neuroscience, infectious diseases, and antimicrobial resistance.

On this page

Overview
Clinical Trials6
Approvals
News1

Back to Organizations